Solid Tumors
📧 Sign up to get email alerts when something new happens for Solid Tumors.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2023-03-30Clinical Trial Update: Nanoparticle Albumin-Bound Rapamycin, Temozolomide, and Irinotecan Hydrochloride in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors [Phase 1]
Phase 1 pediatric trial evaluating a triple combination of nanoparticle albumin-bound rapamycin, temozolomide, and irinotecan for recurrent …
-
CLINICAL_TRIALS trial_result · 2023-03-22Clinical Trial Update: Tomivosertib (eFT-508) in Combination With PD-1/PD-L1 Inhibitor Therapy [Phase 2]
Phase 2 clinical trial update evaluating tomivosertib (eFT-508) in combination with PD-1/PD-L1 inhibitors for solid tumors has completed.
-
CLINICAL_TRIALS trial_result · 2023-03-14Clinical Trial Update: A Study of ICP-192 in Patients With Advanced Solid Tumors [Phase 1, Phase 2]
A clinical trial update for ICP-192 in advanced solid tumors and urothelial carcinoma (Phase 1/2). Status is unknown.
-
CLINICAL_TRIALS trial_result · 2023-03-13Clinical Trial Update: A Clinical Trial Using Metronomic Oral Low-dose Cyclophosphamide Alternating With Low-dose Oral Methotrexate With Continuous Celecoxib and Weekly Vinblastine in Children and Adolescents With Relapsed or Progressing soliD Tumours. [Phase 2]
Phase 2 clinical trial evaluating metronomic cyclophosphamide alternating with methotrexate, continuous celecoxib, and weekly vinblastine in…
-
CLINICAL_TRIALS trial_result · 2023-03-09Clinical Trial Update: A Study of Durvalumab (MEDI4736) and Monalizumab in Solid Tumors [Phase 1, Phase 2]
Clinical trial update for a study of durvalumab and monalizumab in advanced solid tumors (Phase 1/2). The trial is currently active but not …
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2023-03-06Clinical Trial Update: An Investigational Immuno-therapy Study of Experimental Medication BMS-986156, Given by Itself or in Combination With Nivolumab in Patients With Solid Cancers or Cancers That Have Spread. [Phase 1, Phase 2]
Phase 1/2 trial evaluating BMS-986156 alone or with nivolumab in patients with solid tumors; study completed with results posted.
-
CLINICAL_TRIALS trial_result · 2023-03-02Clinical Trial Update: Study of Surufatinib Single Agent or Surufatinib Combined With Toripalimab in Patients With Advanced Solid Tumors [Phase 2]
Phase 2 trial update for surufatinib as a single agent or in combination with toripalimab in patients with advanced solid tumors has complet…
-
CLINICAL_TRIALS trial_result · 2023-02-27Clinical Trial Update: A Study of Ramucirumab (LY3009806) Given by Injection Under the Skin in Participants With Advanced Cancer [Phase 1]
Phase 1 trial update of ramucirumab administered subcutaneously in participants with advanced solid tumors; study terminated with results po…
-
CLINICAL_TRIALS trial_result · 2023-02-22Clinical Trial Update: Efficacy and Safety Study of F520 Combined With Lenvatinib in the Treatment of Patients With Advanced Solid Tumors [Phase 1, Phase 2]
A clinical trial update describes a combined therapy (F520) with lenvatinib for advanced solid tumors across Phase 1 and Phase 2, with no cu…
-
CLINICAL_TRIALS trial_result · 2023-01-25Clinical Trial Update: Study of MK-8353 + Selumetinib in Advanced/Metastatic Solid Tumors (MK-8353-014) [Phase 1]
Phase 1 trial evaluating MK-8353 in combination with selumetinib in advanced/metastatic solid tumors has completed; results posted in 2023.
-
CLINICAL_TRIALS trial_result · 2023-01-18Clinical Trial Update: A Study of MRG003 in the Treatment of Patients With EGFR-positive Advanced or Metastatic Solid Tumors [Phase 1, Phase 2]
A study of MRG003 in EGFR-positive advanced or metastatic solid tumors is ongoing in Phase 1/2; current status is unknown.
-
CLINICAL_TRIALS trial_result · 2023-01-05Clinical Trial Update: Enapotamab Vedotin (HuMax-AXL-ADC) Safety Study in Patients With Solid Tumors [Phase 1, Phase 2]
Phase 1/2 safety study of Enapotamab Vedotin in solid tumors, including ovarian and cervical cancer; completed with posted results.
-
CLINICAL_TRIALS trial_result · 2022-12-28Clinical Trial Update: Testing GDC-0032 (Taselisib) as a Potential Targeted Treatment in Cancers With PIK3CA Genetic Changes (MATCH-Subprotocol I) [Phase 2]
The National Cancer Institute provides an update on the phase 2 MATCH subprotocol evaluating taselisib (GDC-0032) in cancers with PIK3CA gen…
-
CLINICAL_TRIALS trial_result · 2022-12-22Clinical Trial Update: A Trial of Camrelizumab for Injection in Combination With Famitinib Malate Capsule and Paclitaxel For Injection(Albumin Bound) in Advanced Solid Tumors of Patients [Phase 2]
Phase 2 trial evaluating camrelizumab in combination with famitinib and paclitaxel in advanced solid tumors; status is currently unknown.
-
CLINICAL_TRIALS trial_result · 2022-12-12Clinical Trial Update: A Study to Evaluate YH003 in Combination With Toripalimab (Anti-PD-1 mAb) in Subjects With Advanced Solid Tumors [Phase 1, Phase 2]
Phase 1/2 trial evaluating YH003 in combination with toripalimab in advanced solid tumors has completed.
-
CLINICAL_TRIALS trial_result · 2022-12-06Clinical Trial Update: Study to Evaluate Relacorilant (CORT125134) in Combination With Nab-paclitaxel in Participants With Solid Tumors [Phase 1, Phase 2]
Clinical trial evaluating relacorilant in combination with nab-paclitaxel in solid tumors has completed phase 1 and phase 2 with results pos…
-
CLINICAL_TRIALS trial_result · 2022-12-05Clinical Trial Update: Dose Escalation/Dose Expansion Study of YBL-006 in Patients With Advanced Solid Tumors [Phase 1, Phase 2]
Phase 1/2 dose-escalation and dose-expansion study of YBL-006 in patients with advanced solid tumors being conducted, status currently unkno…
-
CLINICAL_TRIALS trial_result · 2022-11-29Clinical Trial Update: Testing Afatinib as a Potential Targeted Treatment in Cancers With HER2 Genetic Changes (MATCH-Subprotocol B) [Phase 2]
A Phase 2 MATCH subprotocol study evaluates afatinib for cancers with HER2 genetic changes; results were posted in 2022 and the trial status…
-
CLINICAL_TRIALS trial_result · 2022-10-24Clinical Trial Update: A Study of Safety, Tolerability and Pharmacokinetics of Nivolumab in Chinese Subjects With Previously Treated Advanced or Recurrent Solid Tumors [Phase 1, Phase 2]
Phase 1/2 trial evaluating safety, tolerability, and pharmacokinetics of nivolumab in Chinese patients with previously treated advanced or r…
-
CLINICAL_TRIALS trial_result · 2022-10-12Clinical Trial Update: Safety and Efficacy of AK104, a PD-1/CTLA-4 Bispecific Antibody, in Selected Advanced Solid Tumors [Phase 1, Phase 2]
Phase 1/2 trial update for AK104, a PD-1/CTLA-4 bispecific antibody, in selected advanced solid tumors and melanoma showing safety and effic…
-
CLINICAL_TRIALS trial_result · 2022-10-05Clinical Trial Update: A Study Comparing Green Fluorescent Dye and Radioactive Dye for Sentinel Lymph Node Biopsy in Pediatric Cancers [Phase 2, Phase 3]
A Phase 2/3 trial comparing green fluorescent dye to radioactive dye for sentinel lymph node biopsy in pediatric solid tumors has completed …
-
CLINICAL_TRIALS trial_result · 2022-09-27Clinical Trial Update: A Phase 1b/2 Study of YL-13027 Combined With Sintilimab in Patients With Advanced Solid Tumors [Phase 1, Phase 2]
A Phase 1b/2 study of YL-13027 in combination with sintilimab in patients with advanced solid tumors is ongoing (Phase 1 and Phase 2).
-
CLINICAL_TRIALS trial_result · 2022-09-23Clinical Trial Update: Pevonedistat, Irinotecan, and Temozolomide in Treating Patients With Recurrent or Refractory Solid Tumors or Lymphoma [Phase 1]
This Phase 1 study evaluated pevonedistat in combination with irinotecan and temozolomide in patients with recurrent or refractory solid tum…
-
CLINICAL_TRIALS trial_result · 2022-09-19Clinical Trial Update: A Study of Telaglenastat (CB-839) in Combination With Palbociclib in Patients With Solid Tumors [Phase 1, Phase 2]
Phase 1/2 trial evaluating Telaglenastat (CB-839) with Palbociclib in solid tumors has completed.
-
CLINICAL_TRIALS trial_result · 2022-09-01Clinical Trial Update: 6MW3511 in Patients With Advanced Solid Tumor [Phase 1, Phase 2]
Clinical trial update for 6MW3511 in advanced solid tumors across Phase 1 and Phase 2.